Simplexa COVID-19 Direct
Device
DiaSorin Molecular LLC
Total Payments
$82,130
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $82,130 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $82,130 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Simplexa COVID-19 Direct: Saliva/NPS Matched Pair Specimen Evaluation - PROT.711.00593 (DD20-008 COVID-19) | DiaSorin Molecular LLC | $82,130 | 0 |
Top Doctors Receiving Payments for Simplexa COVID-19 Direct
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Orange, CA | $82,130 | 2 |
Ad
Manufacturing Companies
- DiaSorin Molecular LLC $82,130
Product Information
- Type Device
- Total Payments $82,130
- Total Doctors 0
- Transactions 2
About Simplexa COVID-19 Direct
Simplexa COVID-19 Direct is a device associated with $82,130 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is DiaSorin Molecular LLC.
Payment data is available from 2021 to 2021. In 2021, $82,130 was paid across 2 transactions to 0 doctors.
The most common payment nature for Simplexa COVID-19 Direct is "Unspecified" ($82,130, 100.0% of total).
Simplexa COVID-19 Direct is associated with 1 research study, including "Simplexa COVID-19 Direct: Saliva/NPS Matched Pair Specimen Evaluation - PROT.711.00593 (DD20-008 COVID-19)" ($82,130).